Fosinorm in the treatment of essential hypertension with metabolic syndrome

The authors made an open non-comparative trial of fosinopril (fosinorm) efficacy and tolerability in 20 patients (9 males and 11 females) with stage II mild and moderate essential hypertension accompanied with disturbed glucose tolerance and dislipidemia. Fosinorm was given in a dose 10-20 mg/day under 24-h monitoring of blood pressure. Diastolic pressure returned to normal in 19(95%) patients, one patient showed a good hypotensive response. The mean 24-h fall in the systolic and diastolic pressure was significant and made up for systolic pressure 6.9% (day-time 5.4%, night-time 6.2%), for diastolic pressure 7.5% (9.2% and 9.2%), respectively. Fosinorm had a minimal effect on carbohydrate metabolism, total cholesterol, serum triglycerides. The conclusion is made that fosinorm is a highly effective antihypertensive drug positively influencing 24-h profile of blood pressure in the absence of negative action on carbohydrate and lipid metabolism.